Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2002 10
2003 9
2004 9
2005 13
2006 7
2007 10
2008 5
2009 11
2010 16
2011 18
2012 7
2013 12
2014 14
2015 11
2016 21
2017 10
2018 26
2019 10
2020 12
2021 9
2022 11
2023 12
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

222 results

Results by year

Filters applied: . Clear all
Page 1
Venglustat in GBA1-related Parkinson's disease.
Zimran A, Revel-Vilk S, Becker-Cohen M, Istaiti M, Rolfs A. Zimran A, et al. Lancet Neurol. 2024 Feb;23(2):137. doi: 10.1016/S1474-4422(23)00455-6. Lancet Neurol. 2024. PMID: 38267177 No abstract available.
Cancer Risk in Patients with Gaucher Disease Using Real-World Data.
Revel-Vilk S, Zimran A, Istaiti M, Azani L, Shalev V, Chodick G, Manor O, Paltiel O. Revel-Vilk S, et al. Among authors: zimran a. J Clin Med. 2023 Dec 15;12(24):7707. doi: 10.3390/jcm12247707. J Clin Med. 2023. PMID: 38137776 Free PMC article.
Insights into the Value of Lyso-Gb1 as a Predictive Biomarker in Treatment-Naïve Patients with Gaucher Disease Type 1 in the LYSO-PROOF Study.
Curado F, Rösner S, Zielke S, Westphal G, Grittner U, Skrahina V, Alasel M, Malik AM, Beetz C, Böttcher T, Barel G, Sah AP, Dinur T, Anjum N, Ichraf Q, Kriouile Y, Hadipour Z, Hadipour F, Revel-Vilk S, Cozma C, Hartkamp J, Cheema H, Zimran A, Bauer P, Rolfs A; LYSO-PROOF Study Group. Curado F, et al. Among authors: zimran a. Diagnostics (Basel). 2023 Aug 30;13(17):2812. doi: 10.3390/diagnostics13172812. Diagnostics (Basel). 2023. PMID: 37685353 Free PMC article.
Reply to Mistry et al. The Two Substrate Reduction Therapies for Type 1 Gaucher Disease Are Not Equivalent. Comment on "Hughes et al. Switching between Enzyme Replacement Therapies and Substrate Reduction Therapies in Patients with Gaucher Disease: Data from the Gaucher Outcome Survey (GOS). J. Clin. Med. 2022, 11, 5158".
Hughes DA, Deegan P, Giraldo P, Göker-Alpan Ö, Lau H, Lukina E, Revel-Vilk S, Scarpa M, Botha J, Gadir N, Zimran A; GOS Steering Committee. Hughes DA, et al. Among authors: zimran a. J Clin Med. 2023 Jun 13;12(12):4017. doi: 10.3390/jcm12124017. J Clin Med. 2023. PMID: 37373710 Free PMC article.
222 results